Cash-Strapped DBV Gets FDA Boost For Peanut Allergy Patch

12 Dec 2024

The French group says it can only fund operations in the first quarter of 2025 but having secured “a clear and reasonable pathway towards an accelerated approval” after talks with the US Food and Drug Administration for its Viaskin Peanut patch in toddlers, the future is looking much brighter.

Just a month after expressing “substantial doubt regarding its ability to continue as a going concern,” DBV Technologies shares are soaring on the news that the French firm has reached agreement with regulators in the US to advance a late-stage study in peanut-allergic toddlers.

The company has trumpeted the successful outcome of recent communication with the US Food and Drug Administration that provides “a...